This approach targeted the fibrotic TME using pirfenidone, an antifibrotic drug that reduces CCL2 and CCL12 production by fibroblasts, which in combination with gemcitabine, reduced tumor volume in mouse models and the levels of tenascin C, fibronectin, and collagen I proteins compared to either gemcitabine or pirfenidone alone [152]. This evidence concerns the gene CCL2 and neoplasm.